For the year ending 2025-12-31, PHGE had -$13,093K decrease in cash & cash equivalents over the period. -$26,392K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Stock-based compensation | 2,091 |
| Gain from early lease termination | 2,949 |
| Finance expense (income), net | -256 |
| Revaluation of contingent consideration | -77 |
| Income from change in fair value of warrants | 6,111 |
| Loss from sale and disposal of fixed assets, net | -205 |
| Ipr&d impairment | 11,842 |
| Other long-lived asset impairment | 1,653 |
| Other current assets | -2,243 |
| Trade account payables | 1,238 |
| Other account payables | -3,430 |
| Net change in operating leases | -74 |
| Depreciation | 2,922 |
| Net loss | -36,199 |
| Private placement warrants issuance cost | 0 |
| Changes in contract liability | 0 |
| Goodwill impairment | 0 |
| Net cash used in operating activities | -26,390 |
| Purchase of property and equipment | 2 |
| Proceeds from sale of property and equipment | 110 |
| Cash and restricted cash acquired from the apt acquisition | 0 |
| Net cash provided by investing activities | 108 |
| Issuance of common stock under february 2025 spa | 996 |
| February 2025 spa issuance costs | 118 |
| Issuance of common warrants under february 2025 spa | 4,531 |
| Issuance of common stock under inducement letter agreements | 6,473 |
| Pre-funded warrants exercise | 2 |
| Issuance of common stock under open market sales agreement, net of issuance costs | 1,305 |
| Repayment of long-term debt | 0 |
| Issuance of private placement warrants under march 2024 pipe | 0 |
| Issuance of redeemable convertible preferred shares under march 2024 pipe | 0 |
| March 2024 pipe issuance costs | 0 |
| Net cash provided by financing activities | 13,189 |
| Increase (decrease) in cash and cash equivalents and restricted cash | -13,093 |
BiomX Inc. (PHGE)
BiomX Inc. (PHGE)